Russian Covid Vaccine Sputnik V Shows 91.4% Efficiency In New Trial: Report

Of the 78 cases, 62 occurred among participants who received a placebo.


Russian developers of coronavirus vaccine released recent results of their trial of the Sputnik V vaccine on Monday based on new data, and said the shot was again 91.4 percent effective in protecting against COVID-19.

More than 100,000 people have already been vaccinated against the disease as part of Russia’s mass inoculation program, which began in September along with a human trial of the shooting in Moscow.

The new results are based on data from 22,714 participants in the trial, and were released after 78 confirmed coronavirus cases were reported among the group, researchers from the Gamaleya Institute said in a statement made Monday with the Russian Direct Investment Fund (RDIF), which markets the shot overseas.

Of the 78 cases, 62 occurred in participants who received placebo, the researchers said, adding that in the process overall the ratio of those who received the placebo to those who were vaccinated was 1 to 3.

Twenty of the infected participants who received placebo suffered severe symptoms of COVID-19, the statement said. There were no severe cases of the disease among the 16 vaccinated participants, the statement said.

Analysis of the new data found that Sputnik V, named after the Soviet-era satellite that launched the space race, had a 91.4 percent efficiency, the statement said.

The results, described as a “final checkpoint” in the trial, were identical to provisional results published on November 24, based on 39 cases of coronavirus among test participants, who also found the shot to be 91.4 percent effective.


“I believe we will be able to vaccinate most of the population in Russia in 2021,” Gamaleya Institute director Alexander Gintsburg was quoted as saying in the statement.

The data will be published by the Gamaleya Institute in an international medical journal by colleagues, according to the statement.

“We will certainly share the results achieved with the scientific community and will be happy to discuss them with all interested colleagues,” said Denis Logunov of Gamaleya Institute.

The results will also be used to send the shot for emergency use to authorize in other countries. Trials of Sputnik V continue in Belarus, the United Arab Emirates, Venezuela and India.

(Except for the headline, this story was not edited by NDTV staff and is published by a union stream.)